14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EDGE vs DERM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Journey Medical Corporation (DERM) is the stronger overall head-to-head candidate over EDGE (EDGE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EDGE carries a Unified Composite Score of 43.7/100 (HOLD) at $46.01 (N/M Forward P/E, N/A operating margin), whereas DERM carries 40.9/100 (SELL) at $3.30 (8.3x Forward P/E, -2.9% operating margin).
Composite vs. Pillar Nuance: While EDGE currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. DERM 40.9/100 SELL), DERM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.9% vs. N/A operating margin) and revenue trajectory (+7.6% vs. N/A YoY).
Technical & Structure Timing Caution: EDGE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.4); meanwhile DERM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EDGE vs DERM. Trailing 12-month operating profitability (EDGE N/A vs DERM -2.9%) and valuation multiples (EDGE N/M vs DERM 8.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $100.2M market capitalization and -2.9% operating margin.
OpEx & R&D Reinvestment68.8% of Rev ($48M)
90D Engineering Disclosures0 Published
Investor FAQ EDGE vs DERM Key Questions & Quantitative Answers
As of Nov 20, 2026, Journey Medical Corporation (DERM) is the stronger overall head-to-head candidate over EDGE (EDGE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EDGE carries a Unified Composite Score of 43.7/100 (HOLD) at $46.01 (N/M Forward P/E, N/A operating margin), whereas DERM carries 40.9/100 (SELL) at $3.30 (8.3x Forward P/E, -2.9% operating margin). Composite vs. Pillar Nuance: While EDGE currently prints a higher short-term Unified Composite Score (43.7/100 HOLD vs. DERM 40.9/100 SELL), DERM captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-2.9% vs. N/A operating margin) and revenue trajectory (+7.6% vs. N/A YoY). Technical & Structure Timing Caution: EDGE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.4); meanwhile DERM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DERM leads the Growth & Scale pillar: EDGE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with DERM at +7.6% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (65.9% gross margin, -2.9% operating margin). On trailing 12-month operating scale, EDGE generates N/A in USD-normalized revenue versus $70M for DERM. In operating R&D and SG&A reinvestment, EDGE deploys N/A (0 90-day corporate R&D disclosures) versus 68.8% of Rev ($48M) (0 disclosures) for DERM.
DERM screens cheaper on headline valuation multiples. EDGE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DERM trades at 8.3x Forward P/E, 17.6x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (-12.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EDGE (N/A ROE) versus DERM (-17.6% ROE) capital efficiency.
In options market volatility and institutional positioning, EDGE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 27% Vol realized risk). By comparison, DERM carries 17.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.08β · 77% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.